论文部分内容阅读
本文作者在轻至中度高血压患者中,以大组多中心试验设计来比较持续释放型地尔硫(艹卓)(DTZ)和氢氯噻嗪(双氢克尿噻,HCTZ)的疗效及安全性.方法:选择原发性高血压患者352例,单盲进入安慰剂筛选期(1～2周),以确立稳定的基础血压.145例因筛选失败或其他问题被剔除.余留207例患者进入调整期(10周).患者随机分为DTZ组100例和HCTZ组107例.两组性别、年龄、种族、身高、体重、吸烟、病程等均相似.患者进行双盲平
The authors compared the efficacy and safety of sustained-release diltiazem (DTZ) and hydrochlorothiazide (hydrochlorothiazide, hydrochlorothiazide, HCTZ) in a large multicenter trial design in patients with mild to moderate hypertension Methods: A total of 352 patients with essential hypertension were enrolled in this study and were enrolled in the placebo screening period (1-2 weeks) to establish stable basal blood pressure.145 patients were excluded due to screening failure or other problems.Other 207 patients The patients were randomly divided into DTZ group (n = 100) and HCTZ group (n = 107) .The gender, age, race, height, weight, smoking, course of disease and so on were similar in both groups.The patients were treated with double-blind